Alumis (ALMS) Net Income towards Common Stockholders (2023 - 2026)
Alumis (ALMS) posted quarterly Net Income towards Common Stockholders of -$92.9 million for Q4 2025, down 181.75% year-over-year from $113.6 million in Q4 2024, and up 16.13% quarter-over-quarter from -$110.8 million in Q3 2025.
Powered by 
Analysis
Alumis (ALMS) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Net Income towards Common Stockholders for 3 consecutive years, with -$92.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Income towards Common Stockholders fell 181.75% year-over-year to -$92.9 million; the TTM figure through Dec 2025 stood at -$250.9 million (down 8.38% YoY), while the FY2025 annual figure was -$243.3 million, down 4.66% from the prior year.
- Net Income towards Common Stockholders improved to -$92.9 million in Q4 2025 per ALMS's latest filing, from -$110.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $59.3 million in Q2 2025 and bottomed at -$110.8 million in Q3 2025.
- Historically, Net Income towards Common Stockholders has averaged -$55.0 million across 3 years, with a median of -$48.9 million in 2024.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 204.98% in 2025 and fell as far as 181.75% in 2025.
- Alumis' Net Income towards Common Stockholders stood at -$41.3 million in 2023, then climbed by 20.16% to -$33.0 million in 2024, then sank by 181.75% to -$92.9 million in 2025.
- Business Quant data shows ALMS's Net Income towards Common Stockholders at -$92.9 million in Q4 2025, -$110.8 million in Q3 2025, and $59.3 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.37 Bn | 130.52 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.18 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.33 Bn | 58.15 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 57.92 Bn | 52.78 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.48 Bn | 32.17 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.38 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Alumis | 1.42 Bn | 913.89 Mn | - | -142.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -142.18 Mn |
| Dec 31, 2025 | -48.64 Mn |
| Sep 30, 2025 | -110.75 Mn |
| Jun 30, 2025 | 59.36 Mn |
| Mar 31, 2025 | -101.53 Mn |
| Dec 31, 2024 | -32.97 Mn |
| Sep 30, 2024 | -93.12 Mn |
| Jun 30, 2024 | -56.51 Mn |
| Mar 31, 2024 | -47.59 Mn |
| Dec 31, 2023 | -40.13 Mn |
| Sep 30, 2023 | -43.76 Mn |
| Jun 30, 2023 | -36.71 Mn |